# A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

> **NCT03653507** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 507 (actual)

## Conditions studied

- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** zolbetuximab
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03653507
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-28
- **Primary completion:** 2022-10-25
- **Final completion:** 2026-09-30
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03653507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03653507, "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03653507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*